z-logo
open-access-imgOpen Access
Sodium–Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease
Author(s) -
Elisabetta Patorno,
Phyo T. Htoo,
Robert J. Glynn,
Sebastian Schneeweiß,
Deborah J. Wexler,
Lily G. Bessette,
Kristyn Chin,
Brendan M. Everett,
Seoyoung Kim
Publication year - 2021
Publication title -
annals of internal medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.839
H-Index - 390
eISSN - 1539-3704
pISSN - 0003-4819
DOI - 10.7326/m21-0893
Subject(s) - medicine , hazard ratio , myocardial infarction , type 2 diabetes , stroke (engine) , diabetes mellitus , population , placebo , heart failure , glucagon like peptide 1 receptor , endocrinology , confidence interval , receptor , mechanical engineering , alternative medicine , environmental health , pathology , engineering , agonist
Both sodium-glucose cotransporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have shown cardiovascular benefits in placebo-controlled trials of patients with type 2 diabetes (T2D) and established cardiovascular disease (CVD).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here